JP2004525899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004525899A5 JP2004525899A5 JP2002565579A JP2002565579A JP2004525899A5 JP 2004525899 A5 JP2004525899 A5 JP 2004525899A5 JP 2002565579 A JP2002565579 A JP 2002565579A JP 2002565579 A JP2002565579 A JP 2002565579A JP 2004525899 A5 JP2004525899 A5 JP 2004525899A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- compound
- compounds
- rapamycin
- coagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- 102400000967 Bradykinin Human genes 0.000 claims 1
- 101800004538 Bradykinin Proteins 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 claims 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 1
- 102100024025 Heparanase Human genes 0.000 claims 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 claims 1
- 108091022875 Microtubule Proteins 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000009949 anti-apoptotic pathway Effects 0.000 claims 1
- 229940046836 anti-estrogen Drugs 0.000 claims 1
- 230000001833 anti-estrogenic effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 1
- 230000009400 cancer invasion Effects 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 230000002074 deregulated effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
- 229960001442 gonadorelin Drugs 0.000 claims 1
- 239000002474 gonadorelin antagonist Substances 0.000 claims 1
- 108010037536 heparanase Proteins 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000004688 microtubule Anatomy 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003277 telomerase inhibitor Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000034512 ubiquitination Effects 0.000 claims 1
- 238000010798 ubiquitination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0104072A GB0104072D0 (en) | 2001-02-19 | 2001-02-19 | Organic compounds |
| GB0124957A GB0124957D0 (en) | 2001-10-17 | 2001-10-17 | Organic compounds |
| PCT/EP2002/001714 WO2002066019A2 (en) | 2001-02-19 | 2002-02-18 | Cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007204409A Division JP2007284454A (ja) | 2001-02-19 | 2007-08-06 | 癌の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004525899A JP2004525899A (ja) | 2004-08-26 |
| JP2004525899A5 true JP2004525899A5 (https=) | 2005-06-09 |
Family
ID=26245731
Family Applications (14)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565579A Pending JP2004525899A (ja) | 2001-02-19 | 2002-02-18 | 癌の処置 |
| JP2007204409A Pending JP2007284454A (ja) | 2001-02-19 | 2007-08-06 | 癌の処置 |
| JP2012101519A Expired - Lifetime JP5775022B2 (ja) | 2001-02-19 | 2012-04-26 | 癌の処置 |
| JP2014095034A Expired - Lifetime JP5873128B2 (ja) | 2001-02-19 | 2014-05-02 | 癌の処置 |
| JP2014114297A Expired - Lifetime JP5879391B2 (ja) | 2001-02-19 | 2014-06-02 | 癌の処置 |
| JP2014114296A Withdrawn JP2014208657A (ja) | 2001-02-19 | 2014-06-02 | 癌の処置 |
| JP2015079430A Expired - Lifetime JP6333766B2 (ja) | 2001-02-19 | 2015-04-08 | 癌の処置 |
| JP2016149701A Expired - Lifetime JP6310970B2 (ja) | 2001-02-19 | 2016-07-29 | 癌の処置 |
| JP2017001065A Expired - Lifetime JP6383814B2 (ja) | 2001-02-19 | 2017-01-06 | 癌の処置 |
| JP2018021354A Expired - Lifetime JP6349476B2 (ja) | 2001-02-19 | 2018-02-08 | 癌の処置 |
| JP2018021353A Expired - Lifetime JP6349475B2 (ja) | 2001-02-19 | 2018-02-08 | 癌の処置 |
| JP2018021352A Expired - Lifetime JP6349474B2 (ja) | 2001-02-19 | 2018-02-08 | 癌の処置 |
| JP2018129096A Withdrawn JP2018168188A (ja) | 2001-02-19 | 2018-07-06 | 癌の処置 |
| JP2020091227A Expired - Lifetime JP6904640B2 (ja) | 2001-02-19 | 2020-05-26 | 癌の処置 |
Family Applications After (13)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007204409A Pending JP2007284454A (ja) | 2001-02-19 | 2007-08-06 | 癌の処置 |
| JP2012101519A Expired - Lifetime JP5775022B2 (ja) | 2001-02-19 | 2012-04-26 | 癌の処置 |
| JP2014095034A Expired - Lifetime JP5873128B2 (ja) | 2001-02-19 | 2014-05-02 | 癌の処置 |
| JP2014114297A Expired - Lifetime JP5879391B2 (ja) | 2001-02-19 | 2014-06-02 | 癌の処置 |
| JP2014114296A Withdrawn JP2014208657A (ja) | 2001-02-19 | 2014-06-02 | 癌の処置 |
| JP2015079430A Expired - Lifetime JP6333766B2 (ja) | 2001-02-19 | 2015-04-08 | 癌の処置 |
| JP2016149701A Expired - Lifetime JP6310970B2 (ja) | 2001-02-19 | 2016-07-29 | 癌の処置 |
| JP2017001065A Expired - Lifetime JP6383814B2 (ja) | 2001-02-19 | 2017-01-06 | 癌の処置 |
| JP2018021354A Expired - Lifetime JP6349476B2 (ja) | 2001-02-19 | 2018-02-08 | 癌の処置 |
| JP2018021353A Expired - Lifetime JP6349475B2 (ja) | 2001-02-19 | 2018-02-08 | 癌の処置 |
| JP2018021352A Expired - Lifetime JP6349474B2 (ja) | 2001-02-19 | 2018-02-08 | 癌の処置 |
| JP2018129096A Withdrawn JP2018168188A (ja) | 2001-02-19 | 2018-07-06 | 癌の処置 |
| JP2020091227A Expired - Lifetime JP6904640B2 (ja) | 2001-02-19 | 2020-05-26 | 癌の処置 |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US8410131B2 (https=) |
| EP (11) | EP2764865A3 (https=) |
| JP (14) | JP2004525899A (https=) |
| KR (3) | KR100695846B1 (https=) |
| CN (5) | CN104116738A (https=) |
| AU (1) | AU2002250968C1 (https=) |
| BR (1) | BR0207378A (https=) |
| CA (3) | CA2994779C (https=) |
| CY (11) | CY1116616T1 (https=) |
| CZ (5) | CZ309247B6 (https=) |
| DK (6) | DK2269604T3 (https=) |
| ES (8) | ES2640787T3 (https=) |
| HK (2) | HK1250018B (https=) |
| HU (1) | HUP0303271A3 (https=) |
| IL (13) | IL157425A0 (https=) |
| LT (9) | LT3342411T (https=) |
| LU (3) | LU92880I2 (https=) |
| MX (3) | MX368013B (https=) |
| NO (14) | NO333105B1 (https=) |
| NZ (1) | NZ527692A (https=) |
| PL (5) | PL231418B1 (https=) |
| PT (7) | PT2762140T (https=) |
| RU (8) | RU2322981C2 (https=) |
| SI (6) | SI3143995T1 (https=) |
| SK (5) | SK288524B6 (https=) |
| TW (2) | TW200626151A (https=) |
| WO (1) | WO2002066019A2 (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| MX368013B (es) * | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
| PL367267A1 (en) * | 2001-06-01 | 2005-02-21 | Wyeth | Antineoplastic combinations |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| US8383605B2 (en) * | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| JP2005535688A (ja) | 2002-07-30 | 2005-11-24 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用 |
| US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
| CA2501610C (en) * | 2002-10-11 | 2012-01-03 | Dana-Farber Cancer Institute Inc | Epothilone derivatives for the treatment of multiple myeloma |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| KR20060085246A (ko) | 2003-09-18 | 2006-07-26 | 마커사이트, 인코포레이티드 | 경공막 전달 |
| EP1721007A2 (en) * | 2004-02-23 | 2006-11-15 | Novartis AG | P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent |
| GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| MXPA06010755A (es) * | 2004-03-23 | 2006-12-15 | Astrazeneca Ab | Terapia de combinacion. |
| DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
| US20090035276A1 (en) | 2005-03-07 | 2009-02-05 | Robarts Research Institute | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
| GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| GB0504995D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
| GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
| JP2009501765A (ja) * | 2005-07-20 | 2009-01-22 | ノバルティス アクチエンゲゼルシャフト | ピリミジルアミノベンズアミドとｍＴＯＲキナーゼ阻害剤の組み合わせ |
| WO2007059106A2 (en) | 2005-11-14 | 2007-05-24 | Ariad Gene Therapeutics, Inc. | Administration of mntor inhibitor to treat patients with cancer |
| NO20220050A1 (no) * | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| KR20080090493A (ko) | 2006-02-02 | 2008-10-08 | 노파르티스 아게 | 결절성 경화증의 치료 |
| GB0602123D0 (en) * | 2006-02-02 | 2006-03-15 | Novartis Ag | Organic compounds |
| KR20140093764A (ko) | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
| US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| EP2056808A4 (en) * | 2006-08-28 | 2009-12-23 | Univ California | Small molecule potentiator of hormonal therapy for breast cancer |
| US9820888B2 (en) | 2006-09-26 | 2017-11-21 | Smith & Nephew, Inc. | Wound dressing |
| EP2131821B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| CN101292980B (zh) * | 2007-04-28 | 2010-11-10 | 上海交通大学医学院附属仁济医院 | 一种含有雷帕霉素的用于治疗大肠癌的药物组合物 |
| WO2009022190A1 (en) * | 2007-08-16 | 2009-02-19 | Biocompatibles Uk Limited | Delivery of drug combinations |
| US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
| US8298200B2 (en) | 2009-06-01 | 2012-10-30 | Tyco Healthcare Group Lp | System for providing continual drainage in negative pressure wound therapy |
| WO2009126965A2 (en) * | 2008-04-11 | 2009-10-15 | The Regents Of The University Of Colorado | Compositions, methods and uses for modulations of brca1 |
| EP2318529B1 (en) * | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| GB0902368D0 (en) | 2009-02-13 | 2009-04-01 | Smith & Nephew | Wound packing |
| GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
| US8791315B2 (en) | 2010-02-26 | 2014-07-29 | Smith & Nephew, Inc. | Systems and methods for using negative pressure wound therapy to manage open abdominal wounds |
| WO2011123691A1 (en) | 2010-03-31 | 2011-10-06 | Keryx Biopharmaceuticals, Inc. | Perifosine and capecitabine as a combined treatment for cancer |
| AU2011290672B2 (en) | 2010-08-20 | 2015-07-09 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| EP3590538A1 (en) * | 2011-12-05 | 2020-01-08 | Novartis AG | Antibodies for epidermal growth factor receptor 3 (her3) |
| CN107095739B (zh) | 2012-05-23 | 2020-11-13 | 史密夫及内修公开有限公司 | 用于负压伤口治疗的装置和方法 |
| EP4699626A3 (en) | 2012-08-01 | 2026-05-06 | Smith & Nephew plc | Wound dressing and method of treatment |
| HUE033329T2 (en) | 2012-08-01 | 2017-11-28 | Smith & Nephew | Wound dressing |
| EP2968648B1 (en) | 2013-03-15 | 2020-12-23 | Smith & Nephew plc | Wound dressing and method of treatment |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| WO2016066608A1 (en) | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging |
| JP6623745B2 (ja) * | 2015-06-29 | 2019-12-25 | 富士通株式会社 | 電子回路及び発振器の制御方法 |
| SMT202100712T1 (it) * | 2015-08-17 | 2022-01-10 | Kura Oncology Inc | Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi |
| EP3429583A1 (en) * | 2016-03-15 | 2019-01-23 | Tyme, Inc. | Pharmaceutical compositions for the treatment of cancer |
| US20200081010A1 (en) | 2016-12-02 | 2020-03-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for diagnosing renal cell carcinoma |
| ES2914123T3 (es) | 2017-01-09 | 2022-06-07 | Shuttle Pharmaceuticals Inc | Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana |
| US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| JP7217241B2 (ja) | 2017-06-30 | 2023-02-02 | ティージェイ スミス アンド ネフュー リミテッド | 陰圧創傷治療装置 |
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| WO2019089556A1 (en) * | 2017-10-31 | 2019-05-09 | Steve Gorlin | Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof |
| CN112004537A (zh) | 2018-01-09 | 2020-11-27 | 穿梭药业公司 | 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂 |
| MX2020011565A (es) | 2018-05-01 | 2021-01-29 | Revolution Medicines Inc | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor. |
| IL312291A (en) | 2018-05-01 | 2024-06-01 | Revolution Medicines Inc | C-26-linked rapamycin analogs as MTOR inhibitors |
| CN108825638A (zh) * | 2018-08-01 | 2018-11-16 | 安徽送变电工程有限公司 | 一种应用于螺纹工件的防盗装置 |
| HRP20250197T1 (hr) | 2018-12-18 | 2025-04-11 | Novartis Ag | Derivati rapamicina |
| GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
| WO2020232227A1 (en) | 2019-05-14 | 2020-11-19 | Tyme, Inc. | Compositions and methods for treating cancer |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| EP4417205A4 (en) | 2021-10-14 | 2025-10-22 | Pharos Ibio Co Ltd | COMPOSITION FOR COMBINATION THERAPY COMPRISING A 2,3,5-SUBSTITUTED THIOPHENE COMPOUND |
| IL317056A (en) | 2022-05-18 | 2025-01-01 | Hadasit Med Res Service | Combining endocannabinoid and MTOR inhibitors in the treatment of neuroendocrine tumors |
| CA3256390A1 (en) | 2022-05-25 | 2023-11-30 | Revolution Medicines, Inc. | CANCER TREATMENT METHODS USING AN MTOR INHIBITOR |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US876165A (en) | 1904-05-11 | 1908-01-07 | George K Woodworth | Wireless telegraph transmitting system. |
| GB104072A (en) | 1916-04-14 | 1917-02-22 | William Henry Nosworthy | Apparatus for Lighting Fires or Heating or other purposes. |
| GB124957A (en) | 1918-06-04 | 1919-04-10 | Frederick William Miller | Improvement in Glass Moulding. |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
| US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| ATE28864T1 (de) | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| JP3140228B2 (ja) * | 1992-02-17 | 2001-03-05 | ファイザー製薬株式会社 | 新規な大環状ラクトンおよびその生産菌 |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| TW225528B (https=) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| AU5151093A (en) | 1992-10-14 | 1994-05-09 | Unichema Chemie Bv | Process for the preparation of alkylglycosides |
| AU687727B2 (en) | 1992-10-28 | 1998-03-05 | Genentech Inc. | Vascular endothelial cell growth factor antagonists |
| US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| GB2273704B (en) * | 1992-12-16 | 1997-01-22 | Orion Yhtymae Oy | Triazolyl diaryl selective aromatase inhibiting compounds |
| DE4301781C2 (de) | 1993-01-23 | 1995-07-20 | Lohmann Therapie Syst Lts | Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| GB9325400D0 (en) | 1993-12-11 | 1994-02-16 | Sarll David P G | Temperature recorder |
| SK78196A3 (en) | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
| WO1995028156A1 (en) * | 1994-04-14 | 1995-10-26 | Sepracor, Inc. | Treating estrogen-dependent diseases with (-)-fadrozole |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| GB9417873D0 (en) | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
| IL129547A (en) | 1994-10-26 | 2001-01-11 | Novartis Ag | Pharmaceutical compositions comprising a macrolide and an acid |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5985890A (en) | 1995-06-09 | 1999-11-16 | Novartis Ag | Rapamycin derivatives |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5567831A (en) * | 1995-08-16 | 1996-10-22 | Duguesne University Of The Holy Ghost | Non-steroidal sulfatase inhibitor compounds and their method of use |
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| DE19544507B4 (de) | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9606452D0 (en) * | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| ATE233098T1 (de) | 1996-06-11 | 2003-03-15 | Novartis Ag | Kombination eines somatostatin analogs und eines rapamycins |
| CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| US6492330B1 (en) * | 1996-08-16 | 2002-12-10 | National Institute Of Immunology | Antiangiogenic drugs |
| US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| EP0927182A2 (en) | 1996-09-09 | 1999-07-07 | American Home Products Corporation | Alkylated rapamycin derivatives |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| EP0954315A2 (en) | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| GB9619631D0 (en) * | 1996-09-20 | 1996-11-06 | British Biotech Pharm | Combination therapy |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US5985325A (en) | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US6015815A (en) * | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6152347A (en) | 1998-01-30 | 2000-11-28 | Acco Brands, Inc. | Vertical Stapler |
| ME00189B (me) | 1998-03-26 | 2011-02-10 | Astellas Pharma Inc | Preparati sa neprekidnim oslobađanjem |
| US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
| CA2326222C (en) * | 1998-04-27 | 2008-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Medicinal compositions |
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| DK1140173T4 (da) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CN1660840A (zh) | 1999-03-30 | 2005-08-31 | 诺瓦提斯公司 | 治疗炎性疾病的酞嗪衍生物 |
| US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
| GB9911582D0 (en) * | 1999-05-18 | 1999-07-21 | Pharmacia & Upjohn Spa | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
| EP1074265A1 (en) | 1999-08-03 | 2001-02-07 | Erasmus Universiteit Rotterdam | Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility |
| JP2003507382A (ja) | 1999-08-18 | 2003-02-25 | ワイス | 水溶性ｓｄｚ−ｒａｄエステル |
| WO2001045740A2 (en) | 1999-12-22 | 2001-06-28 | The Government Of The United States, Department Of Health And Human Services | Compositions and methods for treatment of breast cancer |
| US6899731B2 (en) | 1999-12-30 | 2005-05-31 | Boston Scientific Scimed, Inc. | Controlled delivery of therapeutic agents by insertable medical devices |
| EP1250135B1 (en) * | 2000-01-14 | 2010-07-28 | The Trustees of The University of Pennsylvania | O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| US6641811B1 (en) * | 2000-02-10 | 2003-11-04 | Cornell Research Foundation, Inc. | Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression |
| GB0005257D0 (en) | 2000-03-03 | 2000-04-26 | Pharmacia & Upjohn Spa | Breast cancer hormonal therapy |
| US6761895B2 (en) | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
| US20020013335A1 (en) * | 2000-06-16 | 2002-01-31 | American Home Products Corporation | Method of treating cardiovascular disease |
| GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
| JP2004507465A (ja) | 2000-08-11 | 2004-03-11 | ワイス | エストロゲン受容体陽性癌腫の治療方法 |
| US20050004007A1 (en) * | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| AU2001296558A1 (en) | 2000-10-03 | 2002-04-15 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
| KR20030045847A (ko) | 2000-10-31 | 2003-06-11 | 쿡 인코포레이티드 | 코팅된 이식형 의료 장치 |
| TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| AU2002249826A1 (en) * | 2000-12-22 | 2002-07-30 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
| US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
| MX368013B (es) * | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
| EA010184B1 (ru) | 2001-04-06 | 2008-06-30 | Уайт | Применение противоопухолевых комбинаций рапамицина с гемцитабином или 5-фторурацилом |
| PL367267A1 (en) | 2001-06-01 | 2005-02-21 | Wyeth | Antineoplastic combinations |
| UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| US7488313B2 (en) | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
| JP2003330447A (ja) | 2002-05-15 | 2003-11-19 | Mitsubishi Electric Corp | 画像処理装置 |
| NO20220050A1 (no) | 2005-11-21 | 2008-08-12 | Novartis Ag | Neuroendokrin tumorbehandling |
| RU2609458C2 (ru) | 2011-07-01 | 2017-02-01 | Колопласт А/С | Катетер с баллоном |
| EP2606816A1 (en) | 2011-12-22 | 2013-06-26 | Koninklijke Philips Electronics N.V. | A method and system for providing an indication as to the amount of milk remaining in a breast during lactation |
-
2002
- 2002-02-18 MX MX2014014346A patent/MX368013B/es unknown
- 2002-02-18 NZ NZ527692A patent/NZ527692A/en not_active IP Right Cessation
- 2002-02-18 SK SK50003-2016A patent/SK288524B6/sk unknown
- 2002-02-18 CZ CZ2019-248A patent/CZ309247B6/cs not_active IP Right Cessation
- 2002-02-18 SI SI200231092T patent/SI3143995T1/sl unknown
- 2002-02-18 LT LTEP18155724.0T patent/LT3342411T/lt unknown
- 2002-02-18 CZ CZ2005-91A patent/CZ200591A3/cs not_active IP Right Cessation
- 2002-02-18 PL PL414996A patent/PL231418B1/pl unknown
- 2002-02-18 JP JP2002565579A patent/JP2004525899A/ja active Pending
- 2002-02-18 RU RU2003127391/15A patent/RU2322981C2/ru active
- 2002-02-18 EP EP14164561.4A patent/EP2764865A3/en not_active Withdrawn
- 2002-02-18 SI SI200231088A patent/SI2762140T1/sl unknown
- 2002-02-18 SK SK50008-2016A patent/SK288630B6/sk unknown
- 2002-02-18 CZ CZ2010-473A patent/CZ307940B6/cs not_active IP Right Cessation
- 2002-02-18 WO PCT/EP2002/001714 patent/WO2002066019A2/en not_active Ceased
- 2002-02-18 EP EP18155724.0A patent/EP3342411B1/en not_active Expired - Lifetime
- 2002-02-18 ES ES14164259.5T patent/ES2640787T3/es not_active Expired - Lifetime
- 2002-02-18 DK DK10174985.1T patent/DK2269604T3/en active
- 2002-02-18 PT PT141645655T patent/PT2762140T/pt unknown
- 2002-02-18 EP EP02719864A patent/EP1363627A2/en not_active Withdrawn
- 2002-02-18 CA CA2994779A patent/CA2994779C/en not_active Expired - Lifetime
- 2002-02-18 PT PT18155644T patent/PT3351246T/pt unknown
- 2002-02-18 EP EP10174985.1A patent/EP2269604B1/en not_active Revoked
- 2002-02-18 DK DK18155644.0T patent/DK3351246T3/da active
- 2002-02-18 KR KR1020037010870A patent/KR100695846B1/ko not_active Expired - Lifetime
- 2002-02-18 US US10/468,520 patent/US8410131B2/en not_active Expired - Lifetime
- 2002-02-18 SI SI200231056T patent/SI2269603T1/sl unknown
- 2002-02-18 DK DK16186041.6T patent/DK3143995T3/en active
- 2002-02-18 DK DK14164565.5T patent/DK2762140T3/en active
- 2002-02-18 EP EP18155644.0A patent/EP3351246B8/en not_active Revoked
- 2002-02-18 CA CA2438504A patent/CA2438504C/en not_active Expired - Lifetime
- 2002-02-18 HU HU0303271A patent/HUP0303271A3/hu not_active Application Discontinuation
- 2002-02-18 SK SK902019A patent/SK288834B6/sk unknown
- 2002-02-18 EP EP14164565.5A patent/EP2762140B1/en not_active Revoked
- 2002-02-18 EP EP20100174983 patent/EP2269603B1/en not_active Revoked
- 2002-02-18 SI SI200231094T patent/SI3351246T1/sl unknown
- 2002-02-18 DK DK10174983.6T patent/DK2269603T3/en active
- 2002-02-18 ES ES18155724T patent/ES2744377T3/es not_active Expired - Lifetime
- 2002-02-18 EP EP16186041.6A patent/EP3143995B2/en not_active Expired - Lifetime
- 2002-02-18 CN CN201410286316.1A patent/CN104116738A/zh active Pending
- 2002-02-18 KR KR1020077022986A patent/KR20070102762A/ko not_active Ceased
- 2002-02-18 CN CNB2005100554588A patent/CN1296043C/zh not_active Ceased
- 2002-02-18 PT PT18155724T patent/PT3342411T/pt unknown
- 2002-02-18 CN CN201410286300.0A patent/CN104083365A/zh active Pending
- 2002-02-18 LT LTEP14164565.5T patent/LT2762140T/lt unknown
- 2002-02-18 CN CNA028068440A patent/CN1551767A/zh active Pending
- 2002-02-18 KR KR1020057017585A patent/KR20050095906A/ko not_active Ceased
- 2002-02-18 BR BR0207378-1A patent/BR0207378A/pt not_active Application Discontinuation
- 2002-02-18 CN CN201410469536.8A patent/CN104274442A/zh active Pending
- 2002-02-18 PT PT101749836T patent/PT2269603E/pt unknown
- 2002-02-18 ES ES10174983.6T patent/ES2543383T3/es not_active Expired - Lifetime
- 2002-02-18 SK SK5011-2005A patent/SK288545B6/sk unknown
- 2002-02-18 CZ CZ2018211A patent/CZ309178B6/cs not_active IP Right Cessation
- 2002-02-18 EP EP14164259.5A patent/EP2783686B1/en not_active Revoked
- 2002-02-18 SI SI200231078A patent/SI2269604T1/sl unknown
- 2002-02-18 PT PT101749851T patent/PT2269604T/pt unknown
- 2002-02-18 ES ES18155722T patent/ES2921798T3/es not_active Expired - Lifetime
- 2002-02-18 ES ES14164565.5T patent/ES2629317T3/es not_active Expired - Lifetime
- 2002-02-18 EP EP18181342.9A patent/EP3406249A1/en not_active Withdrawn
- 2002-02-18 PL PL414997A patent/PL414997A1/pl unknown
- 2002-02-18 LT LTEP10174985.1T patent/LT2269604T/lt unknown
- 2002-02-18 PL PL415000A patent/PL415000A1/pl unknown
- 2002-02-18 IL IL15742502A patent/IL157425A0/xx unknown
- 2002-02-18 SI SI200231097T patent/SI3342411T1/sl unknown
- 2002-02-18 LT LTEP18155644.0T patent/LT3351246T/lt unknown
- 2002-02-18 PL PL409579A patent/PL409579A1/pl unknown
- 2002-02-18 SK SK1038-2003A patent/SK288546B6/sk unknown
- 2002-02-18 ES ES18155644T patent/ES2728739T3/es not_active Expired - Lifetime
- 2002-02-18 ES ES10174985.1T patent/ES2600304T3/es not_active Expired - Lifetime
- 2002-02-18 LT LTEP16186041.6T patent/LT3143995T/lt unknown
- 2002-02-18 AU AU2002250968A patent/AU2002250968C1/en not_active Expired
- 2002-02-18 MX MXPA03007418A patent/MXPA03007418A/es active IP Right Grant
- 2002-02-18 PT PT181557224T patent/PT3345602T/pt unknown
- 2002-02-18 CA CA2860306A patent/CA2860306C/en not_active Expired - Lifetime
- 2002-02-18 PT PT16186041T patent/PT3143995T/pt unknown
- 2002-02-18 EP EP18155722.4A patent/EP3345602B1/en not_active Expired - Lifetime
- 2002-02-18 CZ CZ20032209A patent/CZ303611B6/cs not_active IP Right Cessation
- 2002-02-18 PL PL02363918A patent/PL363918A1/xx not_active IP Right Cessation
- 2002-02-18 ES ES16186041T patent/ES2705016T3/es not_active Expired - Lifetime
- 2002-02-18 DK DK18155724.0T patent/DK3342411T3/da active
- 2002-02-19 TW TW095103554A patent/TW200626151A/zh unknown
- 2002-02-19 TW TW091102797A patent/TWI334350B/zh not_active IP Right Cessation
-
2003
- 2003-08-14 IL IL157425A patent/IL157425A/en active IP Right Grant
- 2003-08-18 NO NO20033651A patent/NO333105B1/no not_active IP Right Cessation
- 2003-08-19 MX MX2019010879A patent/MX2019010879A/es unknown
-
2004
- 2004-04-15 HK HK18109527.3A patent/HK1250018B/en not_active IP Right Cessation
- 2004-04-15 HK HK18109752.9A patent/HK1250336B/en not_active IP Right Cessation
-
2005
- 2005-03-01 RU RU2005105664/15A patent/RU2325906C2/ru active
-
2006
- 2006-11-16 RU RU2006140514/15A patent/RU2445093C2/ru not_active IP Right Cessation
-
2007
- 2007-08-06 JP JP2007204409A patent/JP2007284454A/ja active Pending
-
2009
- 2009-11-16 IL IL202155A patent/IL202155A/en active IP Right Grant
-
2011
- 2011-09-22 RU RU2011138835/15A patent/RU2483727C1/ru active
-
2012
- 2012-02-23 US US13/403,474 patent/US20130059877A1/en not_active Abandoned
- 2012-02-23 US US13/403,578 patent/US8436010B2/en not_active Expired - Fee Related
- 2012-04-18 NO NO20120451A patent/NO335134B1/no not_active IP Right Cessation
- 2012-04-26 JP JP2012101519A patent/JP5775022B2/ja not_active Expired - Lifetime
- 2012-05-31 IL IL220095A patent/IL220095A/en active IP Right Grant
- 2012-05-31 IL IL220096A patent/IL220096A/en active IP Right Grant
- 2012-07-11 US US13/546,686 patent/US8778962B2/en not_active Expired - Lifetime
-
2013
- 2013-01-09 NO NO20130045A patent/NO334646B1/no not_active IP Right Cessation
- 2013-04-26 RU RU2013119705A patent/RU2665138C2/ru active
- 2013-05-14 US US13/893,537 patent/US20130253000A1/en not_active Abandoned
- 2013-05-14 US US13/893,589 patent/US20130244951A1/en not_active Abandoned
- 2013-06-27 US US13/928,583 patent/US20130296359A1/en not_active Abandoned
- 2013-06-27 US US13/928,891 patent/US8877771B2/en not_active Expired - Fee Related
- 2013-09-24 RU RU2013143306A patent/RU2659725C2/ru active
- 2013-10-30 IL IL229158A patent/IL229158A/en active IP Right Grant
- 2013-10-30 IL IL229157A patent/IL229157A0/en unknown
- 2013-10-30 IL IL229159A patent/IL229159A0/en unknown
- 2013-10-30 IL IL229156A patent/IL229156A/en active IP Right Grant
- 2013-10-30 IL IL229160A patent/IL229160B/en active IP Right Grant
- 2013-11-19 NO NO20131544A patent/NO336208B1/no not_active IP Right Cessation
- 2013-11-19 NO NO20131545A patent/NO336428B1/no not_active Application Discontinuation
- 2013-11-19 NO NO20131546A patent/NO336110B1/no not_active IP Right Cessation
- 2013-11-19 NO NO20131547A patent/NO336581B1/no not_active IP Right Cessation
- 2013-12-19 US US14/134,419 patent/US20140105895A1/en not_active Abandoned
-
2014
- 2014-05-02 JP JP2014095034A patent/JP5873128B2/ja not_active Expired - Lifetime
- 2014-06-02 JP JP2014114297A patent/JP5879391B2/ja not_active Expired - Lifetime
- 2014-06-02 JP JP2014114296A patent/JP2014208657A/ja not_active Withdrawn
-
2015
- 2015-03-18 NO NO2015010C patent/NO2015010I1/no unknown
- 2015-04-08 JP JP2015079430A patent/JP6333766B2/ja not_active Expired - Lifetime
- 2015-04-09 NO NO20150413A patent/NO20150413L/no not_active Application Discontinuation
- 2015-06-24 NO NO20150831A patent/NO340553B1/no not_active IP Right Cessation
- 2015-07-08 NO NO20150895A patent/NO339240B1/no not_active IP Right Cessation
- 2015-08-13 CY CY20151100711T patent/CY1116616T1/el unknown
- 2015-11-17 LU LU92880C patent/LU92880I2/xx unknown
- 2015-11-19 CY CY2015044C patent/CY2015044I2/el unknown
-
2016
- 2016-06-28 US US15/195,018 patent/US20160303092A1/en not_active Abandoned
- 2016-07-29 JP JP2016149701A patent/JP6310970B2/ja not_active Expired - Lifetime
- 2016-08-24 NO NO20161348A patent/NO340924B1/no not_active IP Right Cessation
- 2016-10-21 CY CY20161101060T patent/CY1118316T1/el unknown
- 2016-11-23 LU LU93320C patent/LU93320I2/fr unknown
- 2016-11-28 LT LTPA2016035C patent/LTC2269604I2/lt unknown
- 2016-12-20 CY CY2016047C patent/CY2016047I2/el unknown
-
2017
- 2017-01-06 JP JP2017001065A patent/JP6383814B2/ja not_active Expired - Lifetime
- 2017-02-20 IL IL250676A patent/IL250676B/en active IP Right Grant
- 2017-03-19 IL IL251270A patent/IL251270B/en active IP Right Grant
- 2017-05-16 NO NO20170803A patent/NO343599B1/no not_active IP Right Cessation
- 2017-06-22 CY CY20171100668T patent/CY1119029T1/el unknown
-
2018
- 2018-02-08 JP JP2018021354A patent/JP6349476B2/ja not_active Expired - Lifetime
- 2018-02-08 JP JP2018021353A patent/JP6349475B2/ja not_active Expired - Lifetime
- 2018-02-08 JP JP2018021352A patent/JP6349474B2/ja not_active Expired - Lifetime
- 2018-05-31 IL IL259724A patent/IL259724B/en unknown
- 2018-06-08 RU RU2018121314A patent/RU2018121314A/ru not_active Application Discontinuation
- 2018-07-06 JP JP2018129096A patent/JP2018168188A/ja not_active Withdrawn
- 2018-07-30 RU RU2018127821A patent/RU2018127821A/ru not_active Application Discontinuation
-
2019
- 2019-01-10 CY CY20191100021T patent/CY1121314T1/el unknown
- 2019-03-04 NO NO20190290A patent/NO20190290A1/no not_active Application Discontinuation
- 2019-06-04 LT LTPA2019511C patent/LTPA2019511I1/lt unknown
- 2019-06-04 LU LU00122C patent/LUC00122I2/fr unknown
- 2019-06-04 CY CY2019030C patent/CY2019030I2/el unknown
- 2019-06-14 CY CY20191100619T patent/CY1121715T1/el unknown
- 2019-09-03 CY CY20191100925T patent/CY1121983T1/el unknown
- 2019-11-21 LT LTPA2019521 patent/LTPA2019521I1/lt unknown
- 2019-11-21 CY CY2019043C patent/CY2019043I1/el unknown
-
2020
- 2020-02-20 LT LTPA2020503C patent/LTPA2020503I1/lt unknown
- 2020-02-20 CY CY2020005C patent/CY2020005I1/el unknown
- 2020-05-26 JP JP2020091227A patent/JP6904640B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004525899A5 (https=) | ||
| RU2003127391A (ru) | Лечение рака | |
| RU2370495C2 (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
| CA2483594A1 (en) | Use of edg receptor binding agents in cancer | |
| EP2266981A3 (en) | Benzothiazole compounds useful as kinase inhibitors | |
| NO2016021I1 (no) | 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2Hpyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft | |
| MX2009005604A (es) | Inhibidores espiro cetona de acetil-coa carboxilasa. | |
| NZ596304A (en) | Substituted aminopropionic derivatives as neprilysin inhibitors | |
| EP2090577A3 (en) | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | |
| EP2275107A3 (en) | Combinations for the treatment of diseases involving cell proliferation | |
| EP2251327A3 (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
| JP2010100637A5 (https=) | ||
| MA34897B1 (fr) | Formulations d'immunosupresseurs | |
| WO2003059898A3 (en) | Eponemycin and epoxomicin analogs and uses thereof | |
| SE0400284D0 (sv) | Novel compounds | |
| EP1721609A3 (en) | Pyridylpyrimidine derivatives as effective compounds against prion diseases | |
| AU2003250471A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| EP2145877A3 (en) | Aurora Kinase inhibitors | |
| WO2024100452A3 (en) | Heterocyclic compounds as sting agonists | |
| BRPI0414663A (pt) | derivados triazol substituìdos como antagonistas de oxitocina | |
| NO20063662L (no) | Benzimidazolderivater | |
| EP2210643A3 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| JP4246997B2 (ja) | 糖尿病由来虚血性心疾患の治療及び／または予防剤 | |
| EP1502916A4 (en) | Piperidin derivatives with CCR3-antagonism | |
| CN1889952A (zh) | (a)N－{5－[4－(4－甲基－(哌嗪－1－基)－甲基)－苯甲酰胺基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺和( b )至少一种羟丁赖氨酸形成抑制剂的组合产品及其用途 |